Recent developments in the drug treatment of Alzheimer's disease

Drugs and Aging

Volumn 14, Issue 5, 1999, Pages 359-373

  Sramek, John J ^a   Cutler, Neal R ^a  

^a CA Clin Trials Med Grp Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ALVAMELINE; ANTIINFLAMMATORY AGENT; ARECOLINE; BETA AMYLASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; HUPERZINE A; IDEBENONE; LAZABEMIDE; MEMANTINE; METRIFONATE; MILAMELINE; MONOAMINE OXIDASE INHIBITOR; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR AGONIST; NERVE GROWTH FACTOR; NICOTINIC AGENT; PHYSOSTIGMINE; PROPENTOFYLLINE; QUILOSTIGMINE; RETINOL; RIVASTIGMINE; SCAVENGER; SELEGILINE; TACRINE; TOCOPHEROL; UNCLASSIFIED DRUG; XANOMELINE;

ADULT; AGED; ALZHEIMER DISEASE; BEHAVIOR; CHOLINERGIC SYSTEM; CHOLINESTERASE INHIBITION; CLINICAL TRIAL; COGNITION; DEGENERATIVE DISEASE; DISEASE COURSE; DRUG COST; DRUG TOLERABILITY; ENZYME RELEASE; ESTROGEN THERAPY; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MUSCLE CRAMP; MUSCLE WEAKNESS; NEUROFIBRILLARY TANGLE; PRIORITY JOURNAL; REVIEW;

EID: 0032961275     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199914050-00004     Document Type: Review

References (150)

1. Cummings JL, Vinters HV, Cole GM, et al. Alzheimers disease: Etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 1998; 51 (1 Suppl. 1): S2-17
2. Small GW. The pathogenesis of Alzheimers disease. J Clin Psychiatry 1998; 59 Suppl. 9: 7-14
3. Small GW. Treatment of Alzheimers disease: Current approaches and promising developments. Am J Med 1998: 104 (4A): 32S-8
4. Tierney MC, Fisher RH, Lewis AJ, et al. The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimers disease: A clinicopathologic study of 57 cases. Neurology 1988; 38 (3): 359-64
5. Flynn DD, Weinstein DA, Mash DC. Loss of high-affinity agonist binding to M1 muscarinic receptors in Alzheimers disease: Implications for the failure of cholinergic replacement therapies. Ann Neurol 1991; 29 (3): 256-62
6. Cummings JL, Back C. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimers disease. Am J Geriatr Psychiatry 1998; 6: S64-78
7. Cacabelos R, Caamano J, Gomez MJ, et al. Therapeutic effects of CDP-choline in Alzheimers disease: Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors. Ann N Y Acad Sci 1996 Jan 17; 777: 399-403
8. Little A, Levy R, Chuaqui-Kidd P, et al. A double-blind, placebo controlled trial of high-dose lecithin in Alzheimers disease. J Neurol Neurosurg Psychiatry 1985; 48 (8): 736-42
9. Heyman A, Schmechel D, Wilkinson W, et al. Failure of long term high-dose lecithin to retard progression of early-onset Alzheimers disease. J Neural Transm 1987; 24 Suppl.: 279-86
10. Farlow MR, Evans, RM. Pharmacologic treatment of cognition in Alzheimers dementia. Neurology 1998; 51 Suppl. 1: S36-44
11. Enz A, Chappuis A, Probst A. Different influence of inhibitors on acetylcholinesterase molecular forms G1 and G4 isolated from Alzheimers disease and control brains. In: Shafferman A, Velan B, editors. Multidisciplinary Approaches to Cholinesterase Functions. New York: Plenum Press, 1992: 243-9
12. Moriarty PL, Becker RE. Inhibition of human brain and RBC acetylcholinesterase (AChE) by heptylphysostigmine (HPTL). Methods Find Exp Clin Pharmacol 1992; 14 (8): 615-21
13. Schegg KM, Harrington LS, Neilsen S, et al. Soluble and membrane-bound forms of Brain acetylcholinesterase in Alzheimers disease. Neurobiol Aging 1992: 13 (6): 697-704
14. Lotti M. Cholinesterase inhibition: Complexities in interpretation. Clin Chem 1995; 41 (12 Pt 2): 1814-8
15. Davis KL, Thal LJ, Gamzu E, et al. A double-blind, placebo controlled multicenter study or tacrine for Alzheimers disease. New Engl J Med 1992; 327(18): 1253-9
16. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimers disease. JAMA 1994; 271 (3); 985-9
17. Raskind MA, Sadowsky CH, Sigmund WR, et al. Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease. Arch Neurol 1997; 54 (7): 836-40
18. Grothe DR, Piscitelli SC, Dukoff R, et al. Penetration of tacrine into cerchrospinal fluid in patients with Alzheimers disease. J Clin Psychopharmacol 1998; 18 (1): 78-81
19. Farlow, MR, Labiri DK, Poirier J, et al. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimers disease. Neurology 1998; 50 (3): 669-77
20. Farlow MR, Lahiri DK, Poirier J, et al. Apolipoprotein E genotype and gender influence response to tacrine therapy. Ann N Y Acad Sci 1996; 802: 101-10
21. Lou G, Montgomery PR, Sitar DS. Bioavailability and pharmacokinetic disposition of tacrine in elderly patients with Alzheimers disease. J Psychiatry Neurosci 1996; 21 (5): 334-9
22. Rogers SL, Doody RS, Mohs RC, Donepezil Study Group, et al. Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998; 158 (9): 102-31
23. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimers disease. Neurology 1998; 50 (1): 136-45
24. Rogers, SL, Friedhoff LT. Long-term efficacy and safety or donepezil in the treatment of Alzheimers disease: An interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1998; 8 (1): 67-75
25. Stewart A, Phillips R, Dempsey G. Pharmacotherapy for people with Alzheimers disease: A Markov-cycle evaluation of five years therapy using donepezil. Int J Geriatr Psychiatry 1998; 13 (7): 445-53
26. Small GW, Donohue JA, Brooks RL. An economic evaluation of donepezil in the treatment of Alzheimers disease. Clin Ther 1998; 20 (4): 838-50
27. Forests Synapton (physostigmine) 'non-approvable'. SCRIP 1998; 2374: 17
28. Thal LJ, Schwartz G, Sano M, Physostigmine Study Group. et al. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimers disease. Neurology 1996; 47 (6): 1389-95
29. Levy A, Brandeis R, Troves TA, et al. Transdermal physostigmine in the treatment of Alzheimers disease. Alzheimer Dis Assoc Disord 1994; 8 (1): 15-21
30. Spencer CM, Noble S, Rivastigmine: A review of its use in Alzheimers Disease. Drugs Aging 1998; 13 (5): 391-411
31. Cutler NR, Polinsky RJ, Sramek JJ, et al. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimers disease. Acta Neurol Scand 1998; 97 (4): 244-50
32. Corey-Bloom J, Anand R, Veach J, ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimers disease. Int J Geriatr Psychopharmacol 1998; 1 (2): 55-65
33. Swedish launch for Exelon. SCRIP 1998; 2349: 19
34. Sramek JJ, Hourani J, Jhee SS, et al. NXX-066 in patients with Alzheimers disease: A bridging study. Life Sci 1999; 64 (14): 1215-21
35. Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimers disease. Neurology 1998; 50 (5): 1222-30
36. Cummings JL, Cyrus PA, Bieber F, et al. Metrifonate treatment of the cognitive deficits of Alzheimers disease. Neurology 1998; 50 (5): 1214-21
37. Becker RE, Colliver JA, Markwell SJ, et al. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimers disease. Alzheimers Dis Assoc Disord 1996; 10(3): 124-31
38. Pettigrew LC, Bieher F, Lettieri J, et al. Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimers disease. J Clin Pharmacol 1998; 38 (3): 236-45
39. Cutler NR, Jhee SS, Cyrus P. et al. Safety and tolerability of metrifonate in patients with Alzheimers disease: Results of a maximum tolerated dose study. Life Sci 1998; 62 (16): 1433-41
40. Bayers metrifonate suspended trials following muscle weakness. SCRIP 1998; 2374: 19
41. Wilcock G, Wilkinson D. Galanthamine hydrobromide: Interim results of a group comparative, placebo-controlled study of efficacy and safety in patients with a diagnosis of senile dementia of the Alzheimer type. In: Iqbal K, Winblad B, Nishimura T, et al., editors. Alzheimers Disease: Biology, Diagnosis and Therapeutics. New York: Wiley, 1997: 661-4
42. Shires galantamine on track for approval. SCRIP 1998; 2354: 24
43. More good news on Shires galantamine. SCRIP 1998; 2356: 21
44. Bores GM, Huger FP, Petko W, et al. Pharmacological evaluation of novel Alzheimers disease therapeutics: Acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther 1996; 277 (2): 728-38
45. Tang XC, Kindel GH, Kozikowski AP, et al. Comparison of the effects of natural and synthetic huperzine-A on rat brain cholinergic function in vitro and in vivo. J Ethnopharmacol 1994; 44 (3): 147-55
46. Cheng DH, Tang XC, Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities. Pharmacol Biochem Behav 1998; 60 (2): 377-86
47. Wang T, Tang XC. Reversal of scopolamine-induced deficits in radial maze performance by (-)-huperzine A: Comparison with E2020 and tacrine. Eur J Pharmacol 1998; 349 (22-31): 137-42
48. Xu SS, Gao ZX, Weng Z, et al. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimers disease. Chung Kuo Yao Li Hsueh Pao 1995; 16 (5): 391-5
49. Cutler NR, Sramek JJ, Veroff AE. Alzheimers Disease: Optimizing Drug Development Strategies. Chichester: Wiley, 1994
50. Mash DC, Flynn DD, Potter LT. Loss of M2 muscarinic receptors in the cerebral cortex in Alzheimers disease and experimental cholinergic denervation. Science 1985; 228: 1115-7
51. 1-receptor agonists: Potential in the treatment of Alzheimers Disease. CNS Drugs 1995; 3 (6): 467-81
52. Sonerant TT, Raffaele KC, Asthana S, et al. Memory improvement without toxicity during chronic, low dose intravenous arecoline in Alzheimers disease. Pyschopharmacology (Berl) 1993; 112 (4): 421-7
53. Raffaele KC, Berardi A, Asthana S, et al. Effects of long-term continuous infusion of the muscarinic cholinergic agonist arecoline on verbal memory in dementia of the Alzheimer type. Psychopharmacol Bull 1991; 27 (3): 315-9
54. Raffaele KC, Berardi A, Morris PP, et al. Effects of acute infusion of the muscarinic cholinergic agonist arecoline on verbal memory and visuo-spatial function in dementia of the Alzheimer type. Prog Neuropsychopharmacol Biol Psychiatry 1991; 15 (5): 643-8
55. Raffaele KC, Asthana S, Berardi A. et al. Differential response to the cholinergic agonist arecoline among different cognitive modalities in Alzheimers disease. Neuropsychopharmacology 1996; 15 (2): 163-70
56. Sramek JJ, Forrest M, Mengel H, et al. A bridging study of LU 25-109 in patients with probable Alzheimers disease. Life Sci 1998; 62 (3): 195-202
57. Forests MI agonist for AD fails. SCRIP 1998; 2364: 16
58. Sramek JJ, Sedman AJ, Recce PA, et al. Safety and tolerability trial of CI-979 in patients with Alzheimers disease. Life Sci 1995; 57 (5): 503-10
59. Cutler NR, Sramek JJ. The target population in phase I clinical trials of cholinergic compounds in Alzheimer disease: The role of the 'bridging study'. Alzheimer Dis Assoc Disord 1995; 9 (3): 139-45
60. Sramek JJ, Hurley DJ, Wardle TS, et al. The safety and tolerance of xanomeline tartrate in patients with Alzheimers disease. J Clin Pharmacol 1995; 35 (8): 800-6
61. Cutler NR, Sramek JJ. Scientific and ethical concerns in clinical trials in Alzheimers patient: The bridging study. Eur J Clin Pharmacol 1995; 48 (6): 421-8
62. Bodick NC, Offen WW, Shannon HE, et al. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Alzheimer Dis Assoc Disord 1997; 11 Suppl. 4; S16-22
63. Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997; 54 (4): 465-73
64. Spiegel R, Brunner C, Ermini-Funfschilling D, et al. A new behavioral assessment scale for geriatric out- and in-patients: The NOSGER (Nurses Observation Scale for Geriatric Patients). J Am Geriatr Soc 1991; 39 (4): 339-47
65. Whitehouse PJ, Martino AM, Antuono PG, et al. Nicotinic acetylcholine binding sites in Alzheimers disease. Brain Res 1986; 371: 146-51
66. Wesnes K, Warburton DM. The effect of cigarette smoking and nicotine tablets upon human attention. In: Thornton RE, editor. Smoking Behaviour: Physiological and Psychological Influences. Edinburgh: Churchill-Livingstone, 1978: 131-47
67. Mangan GL, Golding JF. The effects of smoking on memory consolidation. J Psychol 1983; 115: 65-77
68. Mangan JL. The effects of cigarette smoking on verbal learning and retention. J Gen Psychol 1983; 108: 203-10
69. Ott A, Slooter AJ, Hofman A, et al. Smoking and risk of dementia and Alzheimers disease in a population-based cohort study: The Rotterdam study. Lancet 1998; 351 (9119): 1840-3
70. Hillier V, Salib E. A case-control study of smoking and Alzheimers discase. Int J Geriatr Psychiatry 1997; 12 (3): 295-300
71. Brenner DE, Kukull WA, van Belle G, et al. Relationship between cigarette smoking and Alzheimers disease in a population-based case-control study. Neurology 1993; 43 (2): 293-300
72. Parks RW, Becker RE, Rippey RF, et al. Increased regional cerebral glucose metabolism and semantic memory performance in Alzheimers disease: A pilot double blind transdermal nicotine positron emission tomography study. Neuropsychol Rev 1996; 6 (2): 61-79
73. Yaffe K, Sawaya G, Leiderburg I, et al. Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia. JAMA 1998; 279 (9): 688-95
74. Obkura T, Isse K, Akazawa K, et al. Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. Endocr J 1994; 41 (4): 361-71
75. Simpkins JW, Green PS, Gridley KE, et al. Role of estrogen replacement therapy in memory enhancement and the prevention of neuronal loss associated with Alzheimer's disease. Am J Med 1997; 103 (3A): 19S-25
76. Josefsson E, Tarkowski A, Carlsten H. Anti-inflammatory properties of estrogen: I. In vivo suppression of leukocyte production in bone marrow and redistribution of peripheral blood neutrophils. Cell Immumol 1992; 142 (1): 67-78
77. Behl C, Skutella T, Lezoualch F, et al. Neuroprotection against oxidative stress by estrogens: Structure-activity relationship. Mol Pharmacol 1997; 51: 535-41
78. Xu H, Gouras GK, Greenfield JP, et al. Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat Med 1998, 4 (4): 447-51
79. Baldereschi M, Di Carlo A, Lepore V, et al. Estrogen-replacement therapy and Alzheimers disease in the Italian Longitudinal Study on Aging. Neurology 1998; 50 (4): 996-1002
80. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimers disease: The Baltimore Longitudinal Study of Aging. Neurology 1997: 48 (6): 1517-21
81. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med 1996 28; 156 (19): 2213-17
82. Henderson VW, Watt L, Buckwalter JG. Cognitive skills associated with estrogen replacement in women with Alzheimers disease. Psychoneuroendocrinology 1996; 21 (4); 421-30
83. Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimers disease. Lancet 1996; 348 (9025): 429-32
84. Schneider LS, Farlow MR, Henderson VW, et al. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimers disease. Neurology 1996; 46 (6): 1580-4
85. Schneider LS, Farlow M. Combined tacrine and estrogen replacement therapy in patients with Alzheimers disease. Ann N Y Acad Sci 1997; 826: 317-22
86. Schneider LS, Farlow MR, Pogoda JM. Potential role for estrogen replacement in the treatment of Alzheimers dementia. Am J Med 1997; 103 (3A): 46S-50S
87. Brenner DE, Kukull WA, Stergachis A, et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimers discase: A population-based case-control study. Am J Epidemiol 1994; 149 (3): 262-7
88. Michael CM. Kantor HL. Further psychometric evaluation of older women: The effect of estrogen administration. J Gerontol 1970; 25: 3337-41
89. Rauramo L, Lagerspetz K, Engblom P. The effect of castration and per oral estrogen therapy on some psychological functions. Front Horm Res 1975; 3: 94-104
90. Furujelm M, Fedor-Freybergh P. The influence of estrogen on the psyche in climacteric and post-menopausal women. In: Vankeep PA, Greenblatt RB, Albeaux-Feurnet MM, editors. Consensus on Menopansal Research. Baltimore (MD): University Park Press. 1976: 84-93
91. Vanhulle G, Demo R. A double blind study into the influence of estriol on a number of psychological tests in post-menopausal women. In: Vankeep PA, Greenblatt RB, Albeaux-Feurnet MM, editors. Consensus on Menopausal Research. Baltimore (MD): University Park Press, 1976: 94-9
92. Hackman BW, Galbraith D. Replacement therapy with piperazine oestrone sulfate (harmogen) and its effects on memory. Curr Med Res Opin 1976; 4: 303-6
93. Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology 1988; 13: 345-7
94. Honjo H, Ogino Y, Naitoh K. In vivo effects by estrone sulfate on the central nervous system in senile dementia (Alzeimers type). J Steroid Biochem 1989; 34: 521-5
95. Ditkoff EC, Crary WG, Cristo M. Estrogen improves psychological function in asymptomatic post-menopausal women. Obstet Gynecol 1991; 78: 991-5
96. Phillips SM, Sherwin BB. Estrogen use and verbal memory in healthy post-menopausal women. Obstet Gynecol 1994; 83: 979-83
97. Campbell S, Whitehead M, Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynecol 1997; 4: 33-47
98. Haskell SG, Richardson ED, Horwitz RI. The effect of estrogen replacement therapy on cognitive function in women: A critical review of the literature. J Clin Epidemiol 1997; 50 (11): 1249-97
99. Rozenberg S, Vasquez JB, Vandromme J, et al. Educating patients about the benefits and drawbacks of hormone replacement therapy. Drugs Aging 1998; 13 (1): 33-41
100. Bryant HU, Dere WH. Selective estrogen receptor modulators: An alternative to hormone replacement therapy. Proc Soc Exp Biol Med 1998; 217 (1): 45-52
101. Mitlak BH, Cohen FJ. In search of optimal long-term female hormone replacement: The potential of selective estrogen receptor modulators. Horm Res 1997; 48 (4): 155-63
102. Aisen PS. Inflammation and Alzheimers disease: Mechanisms and therapeutic strategies. Gerontology 1997; 43 (1-2): 143-9
103. Netland EE, Newton JL, Majocha RE, et al. Indomethacin reverses the microglial response to amyloid beta-protein. Neurobiol Aging 1998; 19 (3): 201-4
104. Andersen K, Launer LJ, Ott A, et al. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimers disease? The Rotterdam Study. Neurology 1995; 45 (8): 1441-5
105. Breitner JC, Welsh KA, Helms MJ, et al. Delayed onset of Alzheimers disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 1995; 16 (4): 523-30
106. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimers disease. Neurology 1993; 43 (8): 1609-11
107. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 39: 97-120
108. Celebra to receive priority NDA review. SCRIP 1998; 2365: 14
109. Mercks Vioxx less toxic than ibuprofen. SCRIP 1998; 2396: 20
110. De Leo ME, Borrello S, Passantino M, at AL. Oxidative stress and overexpression of manganese superoxide dismutase in patients with Alzheimers disease. Neurosci Lett 1998; 250 (3): 173-6
111. Li X, De Sarno P, Song L, et al. Peroxynitrite modulates tyrosine phosphorylation and phosphoinositide signalling in human neuroblastoma SH-SY5Y cells: Attenuated effects in human 1321NI astrocytoma cells. Biochem J 1998; 331 (Pt 2): 599-606
112. Mordente A, Martorana GE, Minotti G, et al. Antioxidant properties of 2,3-dimethoxy-5-methyl-6-(10-hydroxygecyl)-1,4-benzoquinone (idebenone). Chem Res Toxicol 1998; 11 (1): 54-63
113. Sugiyama Y, Fujita T. Stimulation of the respiratory and phosphorylating activities in rat brain mitochondria by idebenone (CV-2619), a new agent improving cerebral metabolism. FEBS Lett 1985; 184 (1): 48-51
114. No delisting of nicergoline in Japan. SCRIP 1998; 2346: 17
115. Weyer G, Babej-Dolle RM, Hadler D, et al. A controlled study of two doses of idebenone in the treatment of Alzheimers disease. Neuropsychobiohlogy 1997; 36 (2): 73-82
116. Evans DA, Morris MC. Is a randomized trial of antioxidants in the primary prevention of Alzheimer disease warranted? Alzheimer Dis Assoc Disord 1996; 10 Suppl. 1: 45-49
117. White HL, Stine DK. Monoamine oxidases A and B as components of a membrane complex. J Neurochem 1982; 38 (5): 1429-36
118. Saura J, Andres N, Andrade C. et al. Biphasic and region-specific MAO-B response to aging in normal human brain. Neurobiol Aging 1997; 18 (5): 497-507
119. Gardner DM, Shulman KI, Walker SE, et al. The making of a user friendly MAOI diet. J Clin Psychiatry 1996; 57 (3): 99-104
120. Knoll J, Rationale for (-)deprenyl (selegiline) medication in Parkinsons disease and in prevention of age-related nigral changes. Biomed Pharmacother 1995; 49 (4): 187-95
121. Freedman M, Rewilak D. Xerri T, et al. L-deprenyl in Alzheimers disease: Cognitive and behavioral effects. Neurology 1998; 50 (3): 660-8
122. Marin DB, Bierer LM, Lawlor BA, et al. L-deprenyl and physostigmine for the treatment of Alzheimers disease. Psychiatry Res 1995; 58 (3): 181-9
123. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimers disease. N Engl J Med 1997; 336 ( 17): 1216-22
124. Henriot S, Kuhn C, Kettler R, et al. Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: Preclinical and clinical findings. J Neural Transm Suppl 1994; 41: 321-5
125. Dingemanse J, Wood N, Jorga K, et al. Pharmacokinetics and pharmacodynamics of single and multiple doses of the MAO-B inhibitor lazabemide in healthy subjects. Br J Clin Pharmacol 1997; 43 (1): 41-7
126. Koliatsos VE, Applegate MD, Knusel B, et al. Recombinant human nerve growth factor prevents retrograde degeneration of axotomized basal forebrain cholinergic neurons in the rat. Exp Neurol 1991; 112 (2): 161-73
127. Koliatsos VE, Price DL, Gouras GK, et al. Highly selective effects of nerve growth factor, brain-derived neurotrophic factor, and neurotrophin-3 on intact and injured basal forebrain magnocellular neurons. J Comp Neurol 1994; 343 (2): 247-62
128. Morse JK, Wiegand SJ, Anderson K, et al. Brain-derived neurotrophic factor (BDNF) prevents the degeneration of medial septal cholinergic neurons following fimbria transection. J Neurosci 1993; 13 (10): 4146-56
129. Nitta A, Ogihara Y, Onishi J, et al. Oral administration of propentofylline, a stimulator of nerve growth factor (NGF) synthesis, recovers cholinergic neuronal dysfunction induced by the infusion of anti-NGF antibody into the rat septum. Behav Brain Res 1997; 83 (1-2): 201-4
130. Yamada K, Nitta A, Hasegawa T, et al. Orally active NGF synthesis stimulators: Potential therapeutic agents in Alzheimers disease. Behav Brain Res 1997; 83 (1-2): 117-22
131. Yamada K, Tanaka T, Senzaki K, et al. Propentofylline improves learning and memory deficits in rats induced by beta-amyloid protein-(1-40). Eur J Pharmacol 1998; 349 (1): 15-22
132. Kittner B, Rossner M, Rother M. Clinical trials in dementia with propentofylline. Ann N Y Acad Sci 1997; 826: 307-16
133. Marcusson J, Rother M, Kittner B, European Propenlofylline Study Group, et al. A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. Dement Geriatr Cogn Disord 1997; 8 (5): 3320-8
134. Rother M, Erkinjuntti T, Roessner M, et al. Propentofylline in the treatment of Alzheimers disease and vascular dementia: A review of phase III trials. Dement Geriatr Cogn Disord 1998; 9 Suppl. 1: 36-43
135. Wimo A, Witthaus E, Rother M, et al. Economic impact of introducing propentofylline for the treatment of dementia in Sweden. Clin Ther 1998; 20 (3): 552-66
136. Ditzler K. Efficacy and tolerability of memantine in patients with dementia syndrome: A double-blind, placebo controlled trial. Arzneimittel Forschung 1991; 41 (89): 773-80
137. Görtelmeyer R, Erbler H. Memantine in the treatment of mild to moderate dementia syndrome: A double-blind placebo-controlled study. Arzneimittel Forschung 1992; 42 (7): 904-13
138. Rabey JM, Nissipeanu P, Korezyn AD. Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. J Neural Transm Park Dis Dement Sect 1992; 4: 277-82
139. Hong G, Chen DC, Klein PS, et al. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J Biol Chem 1997; 272 (40): 25326-32
140. Geerts H, Nuydens R, De Jong M, et al. Sabeluzole stabilized the neuronal cytoskeleton. Neurobiol Aging 1996; 17 (4): 573-81
141. Uberti D, Rizzini C, Galli P, et al. Priming of cultured neurons with sabeluzole results in long-lasting inhibition of neurotoxin-induced tau expression and cell death. Synapse 1997; 26 (2): 95-103
142. Lucca E, Angeretti N, Forloni G. Influence of cell culture conditions on the protective effect of antioxidants against beta-amyloid toxicity: Studies with lazaroids. Brain Res 1997; 764 (1-2); 293-8
143. Tomiyama T, Kaneko H, Kataoka K, et al. Rifampicin inhibits the toxicity of pre-aggregated amyloid peptides by binding to peptide fibrils and preventing amyloid-cell interaction. Biochem J 1997: 322 (Pt 3): 859-65
144. Tomiyama T, Shoji A, Kataoka K, et al. Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin: Its possible function as a hydroxyl radical scavenger. J Biol Chem 1996; 271 (12): 6839-44.
145. Schmid-Elsaesser R, Zausinger S, Hungerhuber E, et al. Superior neuroprotective efficacy of a novel antioxidant (U-101033E) with improved blood-brain barrier permeability in focal cerebral ischemia. Stroke 1997; 28 (10): 2018-24
146. Andros PK, Fleck TJ, Oostveen JA, et al. Neuroprotective effects of the novel brain-penetrating pyrrolopyrimidine antioxidants U 101033E and U-104067F against post ischemic degeneration of nigrostriatal neurons. J Neurosci Res 1997; 47 (6): 650-4
147. Cutler NR, Sramek JJ, Kilborn JR. The bridging concept: Optimizing dose for phase II/III in Alzheimers disease. Neurodegeneration 1996; 5 (4): 511-4
148. Cutler NR, Sramek JJ. Optimizing drug development for the next generation of Alzheimers disease compounds. Alzheimers Rep 1998; 1 (5): 1-6
149. Wuest J, Ericson PK, Stern PN. Becoming strangers: The changing family caregiving relationship in Alzheimers disease. J Adv Nurs 1994; 20: 437-43
150. Post SG. Slowing the progression of Alzheimer disease: Ethical issues. Alzheimer Dis Assoc Disord 1997; 11 Suppl. 5; S34-6